Bobin, A., Lambert, J., Corre, J., Manier, S., Perrot, A., Karlin, L., Roussel, M., Bigot, N., Laribi, K., Dingremont, C., Roul, C., Richez, V., Mariette, C., Rigaudeau, S., Calmettes, C., Dib, M., Tiab, M., Vincent, L., Delaunay, J., Marolleau, J. P., Godmer, P., Schavgoulidze, A., Frenzel, L., Calloch, R. L., Chalayer, E., Gardeney, H., Macro, M., Royer, B., Harel, S., Decaux, O., Arnulf, B., Merzoug, K. B., Touzeau, C., Mohty, M., Moreau, P., Facon, T., Hulin, C., Leleu, X. (2025). Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05). Blood. https://doi.org/10.1182/blood-2025-368